上海交通大学学报（医学版）

›› 2012, Vol. 32 ›› Issue (8): 1101-.doi: 10.3969/j.issn.1674-8115.2012.08.030

• 综述 • 上一篇    下一篇

骨质疏松症靶向治疗的研究和应用

王 莹, 杨云梅   

  1. 浙江大学医学院附属第一医院老年医学病房, 杭州 310003
  • 出版日期:2012-08-28 发布日期:2012-08-29
  • 通讯作者: 杨云梅, 电子信箱: lucasmd@126.com。
  • 作者简介:王 莹(1983—), 女, 住院医师, 硕士；电子信箱: wy0939@163.com。

Research and application of target therapy for osteoporosis

WANG Ying, YANG Yun-mei   

  1. Department of Geratology, the First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou 310003, China
  • Online:2012-08-28 Published:2012-08-29

PDF (PC)

1245

摘要：

骨质疏松症是一种常见疾病，是由于骨质和骨微结构的系统性破坏所导致。该病好发于老年人，尤其是绝经后妇女。随着对骨细胞分子生物学认识的不断深入，研究者揭示了骨形成过程中成骨细胞和破骨细胞之间的关键信号系统，并以此为靶点研发出了新的治疗方法。最新治疗策略的目标是抑制额外的骨吸收以及增加新生骨的形成。最有前景的新开发药物包括Denosumab（破骨细胞形成关键信号因子的单克隆抗体）、Odanacatib（破骨细胞蛋白酶——组织蛋白酶K的特异性抑制剂）以及两种内源性骨形成抑制剂（硬化蛋白和Dickkopf-1的抗体）。该文将讨论这些治疗策略的基本原理，并探讨它们的应用前景。

关键词: 骨质疏松症, 靶向治疗, 成骨细胞, 破骨细胞

Abstract:

Osteoporosis is a common disease which is caused by a systemic impairment of bone mass and microarchitecture. The disease is likely to occur in the elderly, especially in postmenopausal women. Along with the understanding of the detailed molecular biology of bone cells, the signaling network of the communication between bone-forming osteoblasts and bone-resorbing osteoclasts has been revealed, which has led to the identification of novel therapeutic targets. Novel treatment strategy aims to inhibit excessive bone resorption and increase bone formation. The most promising novel drugs include denosumab (a monoclonal antibody for a key osteoclast cytokine), odanacatib (a specific inhibitor of the osteoclast protease cathepsin K) and two endogenous inhibitors of bone formation (antibodies against the proteins sclerostin and dickkopf-1). This review will discuss the underlying physiology of novel therapies and explore their further applications.

Key words: osteoporosis, target therapy, osteoblast, osteoclast